EurekaMag
+ Translate
+ Most Popular
Advantages and disadvantages of bordeaux mixture and of lime-sulphur used on apples in the growing season
Observations on the Umaria marine bed
10 years of hearing conservation in the Royal Air Force
Chocolate crumb - dairy ingredient for milk chocolate
Effect of daily gelatin ingestion on human scalp hair
Comparison of rice bran and maize bran as feeds for growing and fattening pigs
The composition of pampas-grass (Cortaderia argentea.)
The Accraian Series:
The mechanism of the Liebermann-Burchard reaction of sterols and triterpenes and their esters
Cerebrovascular Doppler ultrasound studies (cv-Doppler)
Toria: PT-303 - first national variety
Hair growth promoting activity of tridax procumbens
Productivity of Pekin x Khaki Campbell ducks
A stable cytosolic expression of VH antibody fragment directed against PVY NIa protein in transgenic potato plant confers partial protection against the virus
Solar treatment of wheat loose smut
Swimmers itch in the Lake of Garda
Bactofugation and the Bactotherm process
The effects of prefrontal lobotomy on aggressive behavior in dogs
Visual rating scales for screening whorl-stage corn for resistance to fall armyworm
Breakdown of seamounts at the trench axis, viewed from gravity anomaly
Kooken; pennsylvania's toughest cave
Recovery of new dinosaur and other fossils from the Early Cretaceous Arundel Clay facies (Potomac Group) of central Maryland, U.S.A
Zubor horny (Bison bonasus) v prirodnych podmienkach Slovensku
The extended Widal test in the diagnosis of fevers due to Salmonella infection
Hair of the american mastodon indicates an adaptation to a semi aquatic habitat

Therapy for african trypanosomiasis


Therapy for african trypanosomiasis



Current Opinion in Infectious Diseases 4(6): 838-844



ISSN/ISBN: 0951-7375

DOI: 10.1097/00001432-199112000-00020

The main problem in the treatment of human African trypanosomiasis remains the toxicity of the universal and effective drug melarsoprol (4% to 8% lethality during treatment). Other drugs do not penetrate the central nervous system, where the trypanosome migrate very early in the infection before any inflammatory signs appear in the cerebrospinal fluid. DL-.alpha.-Difluoromethylornithine provides an efficient and safe alternative for Trypanosoma brucei gambiense infection, while Trypanosoma brucei rhodesiense is more resistant. Moreover, the administration scheme is spread over 5 weeks including 14 days of intravenous injections. Nifurtimox taken orally for 1 or 2 months has a marked effect on the T. brucei gambiense infection. Too frequent relapses are observed in some trials. Imidazoles, new arsenicals, and antimiotics, were successfully tested in experimental models. Combinations of drugs with additive or potentiating effects mainly based on decarboxylase enzymes or methylating molecules seem promising.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 007946842

Download citation: RISBibTeXText

Related references

Pathology of human African trypanosomiasis with reference to experimental African trypanosomiasis and infections of the central nervous system. British Medical Bulletin 41(2): 169-174, 1985

Therapy of human African trypanosomiasis. La Clinica Terapeutica 41(4): 375-389, 1967

Report on African Trypanosomiasis (Sleeping Sickness): Report of the Scientific Working Group on African Trypanosomiasis, Geneva, 48 June 2001. World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases, Geneva, 2003, x + 169 pp, paperback, TDR/SWG/01. Transactions of the Royal Society of Tropical Medicine and Hygiene 98(6): 392-0, 2004

Therapy of Human African Trypanosomiasis: Current Situation. Memórias do Instituto Oswaldo Cruz 94(2): 221-224, 1999

Therapy of human African trypanosomiasis: current situation. Memorias do Instituto Oswaldo Cruz 94(2): 221-224, 1999

Current status of the therapy of human African trypanosomiasis. Presse Medicale 14(5): 253-256, 1985

African trypanosomiasis and antibodies: implications for vaccination, therapy and diagnosis. Future Microbiology 4(8): 1075-1087, 2009

Ocular disorders and toxic amblyopia during therapy of African trypanosomiasis in humans. Acta Neurologica et Psychiatrica Belgica 55(2): 147-178, 1955

Disappearance of some human African trypanosomiasis transmission foci in Zambia in the absence of a tsetse fly and trypanosomiasis control program over a period of forty years. Transactions of the Royal Society of Tropical Medicine and Hygiene 105(3): 167-172, 2011

Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Medecine Sciences: M/S 22(11): 914-916, 2006

Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrobial Agents and ChemoTherapy 52(10): 3710-3717, 2008

Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nature Medicine 12(5): 580-584, 2006

Specific Cell Targeting Therapy Bypasses Drug Resistance Mechanisms in African Trypanosomiasis. Plos Pathogens 11(6): E1004942, 2015

Correlation of EEG and clinical findings in human African trypanosomiasis and in trypanosomatosis used as therapy of grave psychiatric diseases. Acta Neurologica et Psychiatrica Belgica 55(2): 179-218, 1955

Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis. Research and Reports in Tropical Medicine 3: 93-101, 2012